Dr. Walter Flamenbaum was a Founding Partner of Paul Capital Healthcare Funds, which have invested over $1 billion in forty investments, and is currently a Partner Emeritus where he continues to be available to provide advice to the Fund. His broad based medical knowledge and experience provides the Fund with a valuable resource for healthcare investing.
Dr. Flamenbaum has 40 years of healthcare experience, including the development and evaluation of pharmaceutical and biotechnology based-drugs, medical devices and diagnostics. Prior to joining Paul Capital in 1999 and co-founding Paul Capital Healthcare he spent ten years licensing healthcare product-related intellectual properties and assessing healthcare investing opportunities. Dr. Flamenbaum also founded a contract research organization, started a biomedical company, and had senior management responsibilities in a biotechnology company. His background also includes the leadership of several business organizations including SigA Pharmaceuticals and Therics, Inc.
Dr. Flamenbaum currently serves as a Director of Prism Pharmaceuticals, Inc. and Heart Metabolics Limited. He also served as Director of Oscient Pharmaceuticals Corp.
He is board certified in internal medicine, nephrology, and clinical pharmacology and was a professor of medicine at the Mt. Sinai School of Medicine and Tufts University School of Medicine. Dr. Flamenbaum served in the US Army at the Walter Reed Army Institute of Research and the Walter Reed Army Medical Center. He earned his M.D. from Columbia University’s College of Physicians & Surgeons and his B.A. from Washington & Jefferson College.